Скачать или смотреть Promising efficacy of berzosertib and irinotecan in pancreatic cancer

Liza Villaruz, MD, University of Pittsburgh, Pittsburgh, PA, discusses results from the phase I trial (NCT02595931) of berzosertib, an ATR kinase, and irinotecan in patients with advanced solid tumors. 51 patients were enrolled, with the primary endpoint being the identification of the maximum tolerated dose and recommended phase II dose. The treatment combination was particularly effective in a group of pretreated patients with pancreatic cancer who had deficiencies in ATM, a component of the DNA repair system. Berzosertib and irinotecan were additionally found to be well tolerated in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.